肺がん治療薬の世界市場レポート 2025年

肺がん治療薬の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR11.0％で821億4,000万米ドルに成長します。予測期間の成長は、医療保険と償還政策、ヘルスケアインフラとアクセス、新興市場に起因しています。予測期間における主な動向には、標的療法、免疫療法、ゲノムプロファイリング、臨床試験、調査などの進歩が含まれます。

肺がんの有病率の増加は、肺がん治療薬市場の重要な成長促進要因となっています。この動向は主に肺がん罹患率の上昇に起因しており、効率的かつ迅速な疾患治療のための薬剤の開発と利用可能性が必要とされています。その結果、業界はこの需要増に対応するため、強力な医薬品パイプラインを維持しています。2023年1月現在、米国がん学会は推定23万8,340人の新規肺がん症例を報告し、同年12万7,070人が肺がんで死亡すると予測しています。これらの数字は、肺がんの有病率が増加していることを示しており、肺がん治療薬市場の拡大に拍車をかけています。

肺がん治療薬市場の成長は、喫煙率の増加によってさらに促進されます。肺がんの主な原因である喫煙は、植物、特にタバコ、葉巻、パイプなどさまざまな形のタバコを燃やした煙を吸ったり吐いたりすることに関連しています。例えば、米国を拠点とする非営利団体Global Action to End Smokingによると、2022年にはインドの15歳以上のたばこ使用者は推定2億5,300万人に上り、世界的にみてもたばこ使用者が最も多い国のひとつとなっています。その結果、喫煙率の上昇が肺がん治療薬市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界肺がん治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の肺がん治療薬市場：成長率分析
• 世界の肺がん治療薬市場の実績：規模と成長, 2019-2024
• 世界の肺がん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界肺がん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の肺がん治療薬市場薬物によって、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェムザール
• パラプラチン
• タキソテール
• ナベルビン
• アバスチン
• タルセバ
• イレッサ
• その他の薬物
• 世界の肺がん治療薬市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小細胞肺がん（SCLC）
• 非小細胞肺がん（NSCLC）
• 世界の肺がん治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他のエンドユーザー
• 世界の肺がん治療薬市場ジェムザールの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリックゲムシタビン
• ジェムザールとの併用療法
• 世界の肺がん治療薬市場パラプラチンのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリックカルボプラチン
• パラプラチンとの併用療法
• 世界の肺がん治療薬市場タキソテールのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリックドセタキセル
• タキソテールとの併用療法
• 世界の肺がん治療薬市場ナベルビンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリックビノレルビン
• ナベルビンとの併用療法
• 世界の肺がん治療薬市場アバスチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベバシズマブのバイオシミラー
• アバスチンとの併用療法
• 世界の肺がん治療薬市場タルセバの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリックエルロチニブ
• タルセバとの併用療法
• 世界の肺がん治療薬市場イレッサの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリックゲフィチニブ
• イレッサとの併用療法
• 世界の肺がん治療薬市場その他の医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫チェックポイント阻害剤（ペンブロリズマブ、ニボルマブ）
• 標的療法（オシメルチニブ、クリゾチニブ）
• 化学療法薬（パクリタキセル、シスプラチン）

第7章 地域別・国別分析

• 世界の肺がん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の肺がん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肺がん治療薬市場：競合情勢
• 肺がん治療薬市場：企業プロファイル
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Celgene Corporation
• Mylan N.V.
• Ono Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Ziopharm Oncology Inc.
• Menarini Group
• AstraZeneca PLC
• Shanghai Jinhe Bio-Technology Co. Ltd.
• Nlyte Software
• AbbVie Inc.
• Bayer AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 肺がん治療薬市場2029：新たな機会を提供する国
• 肺がん治療薬市場2029：新たな機会を提供するセグメント
• 肺がん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Lung cancer drugs are a class of anti-angiogenic medications utilized for the treatment of lung cancer, a disease that disrupts the lungs' oxygen supply due to the uncontrolled growth of lung tissues. Potential treatments for lung cancer encompass surgical procedures, chemotherapy, radiation therapy, and targeted therapies. Lung cancer is broadly categorized into two types based on the size of tumor cells such as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

The primary disease categories within the lung cancer drugs sector are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Small cell lung cancer is characterized by rapid growth in lung tissues and often presents with metastasis beyond the lungs at the time of diagnosis. It has a higher likelihood of recurrence after treatment compared to other lung cancer types. Various drugs are used in the treatment of these cancers, including Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, and others. These drugs find application in healthcare settings such as hospitals, clinics, and other medical facilities.

The lung cancer drugs market research report is one of a series of new reports from The Business Research Company that provides lung cancer drugs market statistics, including lung cancer drugs industry, global lung cancer drugs market size, regional shares, competitors with a lung cancer drugs market share, detailed lung cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer drugs industry. This lung cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lung cancer drugs market size has grown rapidly in recent years. It will grow from $47.94 billion in 2024 to $54.13 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to epidemiology and demographics, regulatory approvals, healthcare infrastructure, patient awareness and education.

The lung cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $82.14 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to health insurance and reimbursement policies, healthcare infrastructure and access, emerging markets. Major trends in the forecast period include advancements in targeted therapies, immunotherapy, genomic profiling, clinical trials and research.

The increasing prevalence of lung cancer serves as a significant growth driver for the lung cancer drugs market. This trend is primarily attributed to the rising incidence of lung cancer cases, which necessitates the development and availability of drugs for efficient and rapid disease treatment. Consequently, the industry maintains a robust drug pipeline to address this growing demand. As of January 2023, the American Cancer Society reported an estimated 238,340 new lung cancer cases, with 127,070 deaths from lung cancer expected in the same year. These figures indicate the increasing prevalence of lung cancer, thus fueling the expansion of the lung cancer drugs market.

The growth of the lung cancer drugs market is further propelled by the increasing prevalence of smoking. Smoking, a leading cause of lung cancer, is linked to inhaling and exhaling fumes from burning plant material, particularly tobacco in various forms like cigarettes, cigars, or pipes. For instance, in 2022, according to the Global Action to End Smoking, a US-based non-profit organization, an estimated 253 million people aged 15 and older in India were tobacco users, making it one of the countries with the highest number of tobacco users globally. Consequently, the rising prevalence of smoking is contributing to the growth of the lung cancer drugs market.

The lung cancer drugs market is witnessing an emerging trend in targeted drug therapy in combination with other treatment modalities. This approach involves the utilization of immunotherapy drugs alongside other therapies like chemotherapy to enhance early diagnosis, prevention, and treatment of lung cancer. Leading pharmaceutical manufacturers are actively developing targeted drug therapies to improve the diagnostic and treatment processes for lung cancer. For instance, Merck and Co. have introduced pembrolizumab, a drug that boosts the immune system's ability to identify and combat cancer cells when used in conjunction with chemotherapy. This combination therapy has demonstrated promising outcomes in the management of lung cancer, and it is prominently marketed under the brand name Keytruda.

Major companies operating in the lung cancer drugs market are placing a strong emphasis on the introduction of novel drugs and obtaining regulatory approvals to gain a competitive advantage. The approval of new drugs is a comprehensive process involving requests from pharmaceutical manufacturers or their representatives to regulatory agencies such as the US Food and Drug Administration (FDA). This request is made for the final utilization and commercialization of a new drug for specific indications. As an illustration, in November 2022, Regeneron Pharmaceuticals Inc., a prominent biotechnology firm, announced the FDA's approval of the PD-1 inhibitor Libtayo (cemiplimab-rwlc) for use in combination with platinum-based chemotherapy as the first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC). This approval encompasses patients with locally or metastatically advanced malignancies that are not amenable to definitive chemoradiation or surgical excision. Furthermore, this combination treatment is suitable for patients regardless of histology or PD-L1 expression.

The FDA's regulatory guidelines for lung cancer drugs are delineated in the Code of Federal Regulations (CFR), specifically under Title 21, encompassing subparts from 'A' to 'I'. Subpart 'E' focuses on procedures intended to facilitate the development, assessment, and marketing of drugs designed to treat individuals with life-threatening conditions like lung cancer. These regulations include guidelines for the oversight and evaluation of clinical trials involving lung cancer drugs and other cancer treatments by agency officials. These evaluations aim to determine the safety, efficacy, and comparative benefits of new therapies when compared to existing treatments. Compliance with these FDA regulations is a mandatory requirement for all drug manufacturers in the realm of lung cancer drugs. Consequently, these regulations play a pivotal role in overseeing the activities of lung cancer drug manufacturers and ensuring adherence to rigorous safety and efficacy standards.

Major companies operating in the lung cancer drugs market include Bristol-Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., GlaxoSmithKline PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Celgene Corporation, Mylan N.V., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ziopharm Oncology Inc., Menarini Group, AstraZeneca PLC, Shanghai Jinhe Bio-Technology Co. Ltd., Nlyte Software, AbbVie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eli Lilly and Company Inc., Johnson & Johnson, Amgen Inc., Array BioPharma Inc., Astellas Pharma Inc., Biogen Inc., Clovis Oncology Inc., Eisai Co. Ltd., Exelixis Inc., Genentech Inc., Gilead Sciences Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., Jazz Pharmaceuticals PLC, Karyopharm Therapeutics Inc., Kyowa Kirin Co. Ltd., Loxo Oncology Inc., MedImmune LLC

North America was the largest region in the lung cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the lung cancer drugs market during the forecast period. The regions covered in the lung cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the lung cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The lung cancer drugs market consists of sales of bevacizumab, atezolizumab, and ramucirumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lung Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lung cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lung cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lung cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs: Gemzar; Paraplatin; Taxotere; Navelbine; Avastin; Tarceva; Iressa; Other Drugs
• 2) By Disease Type: Small cell lung cancer (SCLC); Non-small cell lung cancer (NSCLC)
• 3) By End User: Hospitals; Clinics; Other End-Users
• Subsegmentation:
• 1) By Gemzar: Generic Gemcitabine; Combination Therapies With Gemzar
• 2) By Paraplatin: Generic Carboplatin; Combination Therapies With Paraplatin
• 3) By Taxotere: Generic Docetaxel; Combination Therapies With Taxotere
• 4) By Navelbine: Generic Vinorelbine; Combination Therapies With Navelbine
• 5) By Avastin: Biosimilars Of Bevacizumab; Combination Therapies With Avastin
• 6) By Tarceva: Generic Erlotinib; Combination Therapies With Tarceva
• 7) By Iressa: Generic Gefitinib; Combination Therapies With Iressa
• 8) By Other Drugs: Immune Checkpoint Inhibitors (Pembrolizumab, Nivolumab); Targeted Therapies (Osimertinib, Crizotinib); Chemotherapy Drugs (Paclitaxel, Cisplatin)
• Companies Mentioned: Bristol-Myers Squibb Company; Merck & Co. Inc.; F. Hoffmann-La Roche Ltd.; Novartis AG; Pfizer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lung Cancer Drugs Market Characteristics

3. Lung Cancer Drugs Market Trends And Strategies

4. Lung Cancer Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Lung Cancer Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Lung Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Lung Cancer Drugs Market Growth Rate Analysis
• 5.4. Global Lung Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Lung Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Lung Cancer Drugs Total Addressable Market (TAM)

6. Lung Cancer Drugs Market Segmentation

• 6.1. Global Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gemzar
• Paraplatin
• Taxotere
• Navelbine
• Avastin
• Tarceva
• Iressa
• Other Drugs
• 6.2. Global Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small cell lung cancer (SCLC)
• Non-small cell lung cancer (NSCLC)
• 6.3. Global Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End-Users
• 6.4. Global Lung Cancer Drugs Market, Sub-Segmentation Of Gemzar, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Gemcitabine
• Combination Therapies With Gemzar
• 6.5. Global Lung Cancer Drugs Market, Sub-Segmentation Of Paraplatin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Carboplatin
• Combination Therapies With Paraplatin
• 6.6. Global Lung Cancer Drugs Market, Sub-Segmentation Of Taxotere, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Docetaxel
• Combination Therapies With Taxotere
• 6.7. Global Lung Cancer Drugs Market, Sub-Segmentation Of Navelbine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Vinorelbine
• Combination Therapies With Navelbine
• 6.8. Global Lung Cancer Drugs Market, Sub-Segmentation Of Avastin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biosimilars Of Bevacizumab
• Combination Therapies With Avastin
• 6.9. Global Lung Cancer Drugs Market, Sub-Segmentation Of Tarceva, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Erlotinib
• Combination Therapies With Tarceva
• 6.10. Global Lung Cancer Drugs Market, Sub-Segmentation Of Iressa, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Gefitinib
• Combination Therapies With Iressa
• 6.11. Global Lung Cancer Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitors (Pembrolizumab, Nivolumab)
• Targeted Therapies (Osimertinib, Crizotinib)
• Chemotherapy Drugs (Paclitaxel, Cisplatin)

7. Lung Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Lung Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Lung Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lung Cancer Drugs Market

• 8.1. Asia-Pacific Lung Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lung Cancer Drugs Market

• 9.1. China Lung Cancer Drugs Market Overview
• 9.2. China Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lung Cancer Drugs Market

• 10.1. India Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lung Cancer Drugs Market

• 11.1. Japan Lung Cancer Drugs Market Overview
• 11.2. Japan Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lung Cancer Drugs Market

• 12.1. Australia Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lung Cancer Drugs Market

• 13.1. Indonesia Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lung Cancer Drugs Market

• 14.1. South Korea Lung Cancer Drugs Market Overview
• 14.2. South Korea Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lung Cancer Drugs Market

• 15.1. Western Europe Lung Cancer Drugs Market Overview
• 15.2. Western Europe Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lung Cancer Drugs Market

• 16.1. UK Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lung Cancer Drugs Market

• 17.1. Germany Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lung Cancer Drugs Market

• 18.1. France Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lung Cancer Drugs Market

• 19.1. Italy Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lung Cancer Drugs Market

• 20.1. Spain Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lung Cancer Drugs Market

• 21.1. Eastern Europe Lung Cancer Drugs Market Overview
• 21.2. Eastern Europe Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lung Cancer Drugs Market

• 22.1. Russia Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lung Cancer Drugs Market

• 23.1. North America Lung Cancer Drugs Market Overview
• 23.2. North America Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lung Cancer Drugs Market

• 24.1. USA Lung Cancer Drugs Market Overview
• 24.2. USA Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lung Cancer Drugs Market

• 25.1. Canada Lung Cancer Drugs Market Overview
• 25.2. Canada Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lung Cancer Drugs Market

• 26.1. South America Lung Cancer Drugs Market Overview
• 26.2. South America Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lung Cancer Drugs Market

• 27.1. Brazil Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lung Cancer Drugs Market

• 28.1. Middle East Lung Cancer Drugs Market Overview
• 28.2. Middle East Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lung Cancer Drugs Market

• 29.1. Africa Lung Cancer Drugs Market Overview
• 29.2. Africa Lung Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Lung Cancer Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Lung Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lung Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Lung Cancer Drugs Market Competitive Landscape
• 30.2. Lung Cancer Drugs Market Company Profiles
  • 30.2.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Lung Cancer Drugs Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Sanofi S.A.
• 31.3. Sun Pharmaceutical Industries Ltd.
• 31.4. Celgene Corporation
• 31.5. Mylan N.V.
• 31.6. Ono Pharmaceutical Co. Ltd.
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Takeda Pharmaceutical Company Limited
• 31.9. Ziopharm Oncology Inc.
• 31.10. Menarini Group
• 31.11. AstraZeneca PLC
• 31.12. Shanghai Jinhe Bio-Technology Co. Ltd.
• 31.13. Nlyte Software
• 31.14. AbbVie Inc.
• 31.15. Bayer AG

32. Global Lung Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lung Cancer Drugs Market

34. Recent Developments In The Lung Cancer Drugs Market

35. Lung Cancer Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Lung Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Lung Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Lung Cancer Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer